October 2024

Lalan Wilfong, MD, a 20-year medical oncologist with Texas Oncology, is senior vice president, value-based care, Thyme Care.

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot receive an autologous stem cell transplant to treat their newly diagnosed multiple myeloma.

Coverage from the Institute for Value-Based Medicine session at Ohio State University. This article will appear in the October issue of Evidence-Based Oncology.

The National Comprehensive Cancer Network Policy Summit emphasized the importance of integrating diversity, equity, and inclusion into the oncology workforce to improve cancer care outcomes and address disparities while navigating legal and societal challenges.